G
Gyre Therapeutics, Inc. (GYRE)
NCM – Real vaqt narxi. Valyuta: USD
6.29
+0.06 (0.96%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
6.34
+0.05 (0.79%)
Bozordan keyin: Jun 26, 2026, 5:08 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
6.29
+0.06 (0.96%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
6.34
+0.05 (0.79%)
Bozordan keyin: Jun 26, 2026, 5:08 PM EDT
Gyre Therapeutics, Inc., farmatsevtika kompaniyasi, organ fibroziga qaratilgan kichik molekulali, yallig'lanishga qarshi va fibrozga qarshi dorilarni ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniya ETUARY (Pirfenidone)ni taklif etadi, bu fibrozga qarshi dori bo'lib, idiopatik o'pka fibrozini davolash uchun tasdiqlangan; va pnevmokoniozni davolash uchun III bosqich sinovlarida. Shuningdek, u ETUARYning tuzilma hosilasi bo'lgan F351 (Hydronidone)ni ishlab chiqishda ishtirok etadi, bu surunkali gepatit B (CHB) bilan bog'liq jigar fibrozini davolash uchun III bosqich sinovlarida; va metabolik disfunktsiya bilan bog'liq steatohepatit bilan bog'liq jigar fibrozini davolash uchun I bosqich sinovlarini yakunlagan. Bundan tashqari, kompaniya F573ni ishlab chiqadi, u o'tkir/surunkali jigar etishmovchiligini davolash uchun II bosqich klinik sinovlarida. Shuningdek, uning preklinik mahsulotlari o'pka arteriya gipertenziyasini davolash uchun F230; va surunkali obstruktiv o'pka kasalligini davolash uchun F528ni o'z ichiga oladi. Gyre Therapeutics, Inc. 2002 yilda tashkil etilgan va San-Diego, Kaliforniyada joylashgan. Gyre Therapeutics, Inc. GNI USA, Inc.ning sho'ba korxonasi sifatida faoliyat yuritadi.
| Ism | Lavozim |
|---|---|
| Dr. Ying Luo Ph.D. | CEO, President & Director |
| Dr. Yue Xiong Ph.D. | Chief Scientific Officer |
| Jing Liu Ph.D. | Senior Vice President of Platform Chemistry |
| Mark Marino | Senior Vice President of Clinical Development |
| Mr. Jialiang Wang Ph.D. | Executive VP & GM |
| Mr. Joshua Bergmann J.D. | General Counsel & Corporate Secretary |
| Mr. Thomas W. Eastling M.D. | Chief Financial Officer |
| Mr. Weiguo Ye | Chief Operating Officer |
| Ms. Ruoyu Chen | Chief Information Officer |
| Seth Goldblum M.B.A. | Senior Vice President of Corporate Development |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-23 | S-3 | ny20070577x1_s3.htm |
| 2026-06-16 | 8-K | ef20076059_8k.htm |
| 2026-06-10 | S-8 | ef20075357_s8.htm |
| 2026-06-02 | 8-K | ef20075381_8k.htm |
| 2026-05-14 | 8-K | ef20073544_8k.htm |
| 2026-05-12 | 8-K | ef20073066_8k.htm |
| 2026-05-08 | 10-Q | gyre-20260331.htm |
| 2026-05-07 | 8-K | gyre-20260507.htm |
| 2026-05-04 | DEFA14A | ef20072214_defa14a.htm |
| 2026-05-04 | 8-K | ef20072211_8k.htm |